Iloprost Zentiva Pharma

Iloprost, the active ingredient in Iloprost Zentiva Pharma, is a prostacyclin analog presented as an inhalation solution for inhalation use. It treats pulmonary arterial hypertension and digital ulcers associated with systemic sclerosis in adult patients.

GNH USA supplies Iloprost Zentiva Pharma as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Iloprost acts on the prostacyclin pathway to provide vasodilation and antiplatelet effects in specific vascular diseases.

Pulmonary arterial hypertension: improves exercise capacity and delays disease progression. Digital ulcers associated with systemic sclerosis: promotes ulcer healing and reduces formation of new ulcers.

Iloprost may cause a range of adverse reactions, most of which are mild and reversible.

Common Side Effects: - Cough - Throat irritation - Headache - Flushing

Serious or Rare Side Effects: - Hypotension - Severe bronchospasm - Bleeding events

When using Iloprost, clinicians should consider several safety measures.

Monitor blood pressure: watch for symptomatic hypotension. Assess bleeding risk: avoid in patients with active hemorrhage. Evaluate pulmonary function: ensure adequate baseline lung capacity. Avoid concomitant potent vasodilators: may amplify hypotensive effects. Use with caution in recent hemoptysis: risk of pulmonary bleeding. Store at room temperature: keep in original container, protect from light and moisture.

Iloprost can interact with other medicines, requiring attention to avoid adverse outcomes.

Major Interactions (Avoid): - Other prostacyclin analogs: additive vasodilatory effect. - Potent vasodilators (e.g., nitroglycerin): may cause severe hypotension. - Anticoagulants (e.g., warfarin): increased bleeding risk.

Moderate Interactions (Monitor Closely): - NSAIDs: may blunt antiplatelet action. - Calcium channel blockers: potential additive blood‑pressure lowering. - Beta‑blockers: may interfere with compensatory heart‑rate response.